Abbisko Therapeutics' Lavengratinib Receives EMA Orphan Drug Designation for the Treatment of Achondroplasia

On October 21, Abbisko Therapeutics announced that its independently developed selective oral small molecule FGFR2/3 inhibitor lavengratinib for the treatment of achondroplasia has been granted orphan drug designation by the European Medicines Agency.